Tag Archives: hydroxychloroquine
On The Lancet editorial
On May 8, The Lancet published an editorial criticising the Narendra Modi government’s response to India’s second COVID-19 outbreak, which has been redefining the meaning of ‘snafu’. All hell broke loose. Of course, hell has been breaking loose for quite … Continue reading
Posted in Scicomm
Tagged COVID-19 epidemic, COVID-19 in India, COVID-19 pandemic, Dr Harsh Vardhan, favipiravir, hydroxychloroquine, Pankaj Chaturvedi, second wave, The Lancet, whataboutery
Comments Off on On The Lancet editorial
Spray and pray – the COVID-19 version
Kiran Mazumdar-Shaw is the head of Biocon, a company headquartered in Bengaluru and which has repurposed a drug called itolizumab – already approved to help manage severe chronic psoriasis in different markets – to manage cytokine release syndrome (CRS) in … Continue reading
Posted in Science
Tagged azithromycin, Biocon, chyavanprash, COVID-19, cytokine release syndrome, cytokine storm, favipiravir, hydroxychloroquine, Itolizumab, Kiran Mazumdar-Shaw, novel coronavirus, psoriasis, The Print
Comments Off on Spray and pray – the COVID-19 version
India’s missing research papers
If you’re looking for a quantification (although you shouldn’t) of the extent to which science is being conducted by press releases in India at the moment, consider the following list of studies. The papers for none of them have been … Continue reading
Posted in Science
Tagged Bharat Biotech, Biocon, Covaxin, COVID-19, COVID-19 epidemic, COVID-19 pandemic, ELISA test kit, favipiravir, hydroxychloroquine, Indian Council of Medical Research, Itolizumab, novel coronavirus, peer review, preprint papers, remdesivir, science academies, science by press release, seroprevalence survey, Tata Institute of Fundamental Research, tocilizumab, Zydus Cadila
Comments Off on India’s missing research papers
A non-self-correcting science
While I’m all for a bit of triumphalism when some component of conventional publication vis-à-vis scientific research – like pre-publication anonymous peer review – fails, and fails publicly, I spotted an article in The Conversation earlier today that I thought … Continue reading
Posted in Science
Tagged COVID-19, hydroxychloroquine, New England Journal of Medicine, peer review, science publishing, scientific publishing, The Conversation, The Lancet
Comments Off on A non-self-correcting science
The costs of correction
I was slightly disappointed to read a report in the New York Times this morning. Entitled ‘Two Huge COVID-19 Studies Are Retracted After Scientists Sound Alarms’, it discussed the implications of two large studies of COVID-19 recently being retracted by … Continue reading
Posted in Science
Tagged COVID-19, Elisabeth Bik, hydroxychloroquine, New England Journal of Medicine, New York Times, peer review, preprint papers, preprints, scientific literature, scientific publishing, The Lancet
Comments Off on The costs of correction
A caveat for peer-review
Now that more researchers are finding more holes in the study in The Lancet, which claimed hydroxychloroquine – far from being a saviour of people with COVID-19 – actually harms them, I wonder where the people are who’ve been hollering … Continue reading
Posted in Science
Tagged Andrew Gelman, chloroquine, COVID-19, hydroxychloroquine, macrolide, open review, peer review, preprint server, The Lancet
Comments Off on A caveat for peer-review
‘Science alone triumphs’: A skeptic annotates
An article entitled ‘Science alone triumphs: Providing a true picture of the world, only science can help India against coronavirus’, penned by a Jayant Sinha, appeared on the Times of India‘s editorials page on April 8, 2020. My annotated reading … Continue reading
Posted in Analysis, Science
Tagged Bharatiya Janata Party, COVID-19, hydroxychloroquine, Indian Council of Medical Research, Jayant Sinha, novel coronavirus, virus
Comments Off on ‘Science alone triumphs’: A skeptic annotates